<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Contract</title>
	<atom:link href="http://www.tapanray.in/tag/contract/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma SMEs in India: a quick overview</title>
		<link>http://www.tapanray.in/pharma-smes-in-india-a-quick-overview/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-smes-in-india-a-quick-overview</link>
		<comments>http://www.tapanray.in/pharma-smes-in-india-a-quick-overview/#comments</comments>
		<pubDate>Mon, 01 Feb 2010 00:30:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[CRMS]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[overview]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[SMEs]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=473</guid>
		<description><![CDATA[The spread of Pharma SMEs in India: As per a recent study by Dun and Bradstreet, largest cluster of the Pharma SMEs is located in the western region of India contributing almost 55% of the total SMEs, based mostly in &#8230; <a href="http://www.tapanray.in/pharma-smes-in-india-a-quick-overview/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-smes-in-india-a-quick-overview/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India as a global pharmaceutical outsourcing hub: Some key advantages and the areas of improvement.</title>
		<link>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement</link>
		<comments>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/#comments</comments>
		<pubDate>Mon, 04 Jan 2010 00:30:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[advantages]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[areas]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[hub]]></category>
		<category><![CDATA[improvement]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Some]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=488</guid>
		<description><![CDATA[All over the world, pharmaceutical research and development pipelines are gradually getting dried up. Lesser and lesser blockbuster drugs are now coming up from the ‘mind to the market’. Currently the average annual turnover of over 90% of patented drugs &#8230; <a href="http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Contract Research – a rapidly evolving business opportunity in India: Is the Pharmaceutical Industry making the best use of it?</title>
		<link>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it</link>
		<comments>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/#comments</comments>
		<pubDate>Thu, 02 Jul 2009 01:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[best]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rapidly]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=845</guid>
		<description><![CDATA[A quick perspective of the ‘new-era’ pharmaceutical R&#38;D in India: Since 1970 up until 2005, Indian pharmaceutical industry used to be considered as the industry of ‘reverse engineering’ and that too with an underlying disparaging tone&#8230; and also as the &#8230; <a href="http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Global ‘Contract Research and Manufacturing Services’ (CRAMS) – a new growth opportunity for mid-cap Indian pharmaceutical companies&#8230; Are we ready?</title>
		<link>http://www.tapanray.in/global-contract-research-and-manufacturing-services-crams-a-new-growth-opportunity-for-mid-cap-indian-pharmaceutical-companies-are-we-ready/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=global-contract-research-and-manufacturing-services-crams-a-new-growth-opportunity-for-mid-cap-indian-pharmaceutical-companies-are-we-ready</link>
		<comments>http://www.tapanray.in/global-contract-research-and-manufacturing-services-crams-a-new-growth-opportunity-for-mid-cap-indian-pharmaceutical-companies-are-we-ready/#comments</comments>
		<pubDate>Sat, 27 Jun 2009 01:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[mid-cap]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=854</guid>
		<description><![CDATA[Intense competition within global pharmaceutical industry, patent expiries of blockbuster drugs, ballooning R&#38;D costs together with low R&#38;D productivity, more and more stringent regulatory standards coupled with intense cost containment measures are exerting intense pressure on the bottom lines of &#8230; <a href="http://www.tapanray.in/global-contract-research-and-manufacturing-services-crams-a-new-growth-opportunity-for-mid-cap-indian-pharmaceutical-companies-are-we-ready/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/global-contract-research-and-manufacturing-services-crams-a-new-growth-opportunity-for-mid-cap-indian-pharmaceutical-companies-are-we-ready/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
